莫西沙星治疗下呼吸道感染疗效与安全性研究

Clinical Study on Moxifloxacin in Treatment of Low Respiratory Tract Infection

目的 :评价新一代氟喹诺酮类抗菌药物莫西沙星片剂治疗下呼吸道感染的疗效与安全性。方法 :莫西沙星片与左旋氧氟沙星片随机对照治疗下呼吸道感染共 6 4例 ,莫西沙星组 33例 (男性 13例 ,女性 2 0例 ,年龄 6 0 .9± 10 .6 8) ,左旋氧氟沙星组 31例 (男性 13例 ,女性 18例 ,年龄 5 6 .0± 13.5 5 )。剂量均为 4 0 0mg ,po ,qd和 2 0 0mg ,po ,bid ;疗程均为 7～ 14天。结果 :莫西沙星和左旋氧氟沙星治疗下呼吸道感染的有效率分别为 6 6 .7%和 5 8.1% ,细菌清除率均为 10 0 % ,不良反应发生率分别为 5 .5 6 %和 11.1% ,2组比较均无显著性差异 ,P >0 .0 5。结论 :莫西沙星片剂治疗下呼吸道感染疗效确切 ,安全性好。

Objective: To evaluate a newer fluquinolone, moxifloxacin curative effect and safety in treatment of low respiratory tract.Methods: 64 cases of patients with low respiratory tract infection were given randomly noxifloxacin tablet and ofloxacin, respectively. Moxifloxacin group included 33 cases, ofloxacin group 31 case. Doses of both groups were 400 mg, po, qd and 200 mg, po, bid, respectively. The therapy duration was 7 14 days. Results: The effective rates of both groups were 66.7% and 58.1% , the bacterial clearences of both groups all were 100%, the incidences of ADRs in both groups were 5.56% and 11.1% , respectively. There was no a significant difference between both groups( P > 0.05 ).Conclusion: The curative effect is definite and safe with moxifloxacin in treatment of low respiratory tract infection.